No abstract

Objective To determine the extent of cerebral palsy attributable to adverse obstetric events, and estimate the lifetime mortality and morbidity expectations of these individuals relative to age-matched members of the UK general population.Design Simulation model. Setting UK.Population All projected live births during 2014.Methods Using published data regarding the incidence and aetiology of cerebral palsy, we simulated the outcomes of a hypothetical cohort of UK live births. Survival and quality of life (QoL) for those with cerebral palsy were compared with age-matched individuals representative of the UK general population, in order to estimate the number of quality-adjusted life years (QALYs) lost following asphyxia-related cerebral palsy.Main outcome measures Incidence of asphyxia-related cerebral palsy, QALYS, QoL, and survival. Conclusions Cerebral palsy following intrapartum asphyxiation leads to significant reductions in QoL and survival; however, this may often be prevented. For those with GMFCS 1 and GMFCS 2 cerebral palsy (Gross Motor Function Classification System), lifetime QALYs accrued largely resemble those experienced by the UK general population, whereas for GMFCS 3 and GMFCS 4 QALYs are reduced considerably, and are negative in the case of GMFCS 5.

ObjectiveTo determine the effectiveness and economic impact of two methods for induction of labour in hypertensive women, in low‐resource settings.DesignCost‐consequence analysis of a previously reported multicentre, parallel, open‐label randomised trial.Setting & populationA total of 602 women with a live fetus, aged ≥18 years requiring delivery for pre‐eclampsia or hypertension, in two public hospitals in Nagpur, India.MethodsWe performed a formal economic evaluation alongside the INFORM clinical trial. Women were randomised to receive transcervical Foley catheterisation or oral misoprostol 25 mcg. Healthcare expenditure was calculated using a provider‐side microcosting approach.Main outcome measuresRates of vaginal this delivery within 24 hours of induction, healthcare expenditure per completed treatment episode.ResultsInduction with oral misoprostol resulted in a (mean difference) $20.6USD reduction in healthcare expenditure [95% CI (−) $123.59 (−) $72.49], and improved achievement of vaginal delivery within 24 hours of induction, mean difference 10% [95% CI (−2 to 17.9%), P = 0.016]. Oxytocin administration time was reduced by 135.3 minutes [95% CI (84.4–186.2 minutes), P < 0.01] and caesarean sections by 9.1% [95% CI (1.1–17%), P = 0.025] for those receiving oral misoprostol. Following probabilistic sensitivity analysis, oral misoprostol was cost‐saving in 63% of 5,000 bootstrap replications and achieved superior rates of vaginal delivery, delivery within 24 hours of induction and vaginal delivery within 24 hours of induction in 98.7%, 90.7%, and 99.4% of bootstrap simulations. Based on univariate threshold analysis, the unit price of oral misoprostol 25 mcg could feasibly increase 31‐fold from $0.24 to $7.50 per 25 mcg tablet and remain cost‐saving.ConclusionCompared to Foley catheterisation for the induction of high‐risk hypertensive women, oral misoprostol improves rates of vaginal delivery within 24 hours of induction and may also reduce costs. Additional research performed in other low‐resource settings is required to determine their relative cost‐effectiveness.Tweetable abstractOral misoprostol less costly and more effective than Foley catheter for labour induction in hypertension.

(Abstracted from Lancet 2017;390:669–680) Hypertensive disorders of pregnancy such as preeclampsia are leading causes of maternal morbidity and mortality worldwide and can be reduced by an expeditious delivery. In places where resources are scarce (both personnel and equipment to carefully monitor mother and child during labor), 2 inexpensive methods of induction to more quickly get active labor going are recommended by the World Health Organization: use of a transcervical Foley catheter or low-dose oral misoprostol pills.